OKLAHOMA CITY, OK–(Marketwired – November 03, 2015) – Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.

Under the terms of the Agreement, Cytovance® Biologics will scale up and optimize the manufacturing process of M-001. The transfer of technology will start immediately, with the Phase III batches manufactured as soon as Q4 2016. The M-001 batch will be used by BiondVax in a phase III trial planned for 2017-2018.

Ron Babecoff, CEO of BiondVax commented: “This strategic partnership with Cytovance® Biologics, a US leader in contract manufacturing with a significant track record in production of clinical materials, is very important to BiondVax. I am pleased to see our clinical program is now taking a significant step forward. This manufacturing agreement marks a major milestone towards our progression to the advanced phases of our clinical development program.”

Darren Head, CEO and President of Cytovance added: “Cytovance’s state-of-the-art facilities and staff are prepared to deliver the highest quality of manufacturing services for BiondVax.”